Objective: To explore the relationship between anti-
human leukocyte antigen (HLA)
antibodies and
transplant outcomes in
patients with
hematological diseases who underwent matched
sibling donor transplantation (MSDT).
Methods: A retrospective
analysis was conducted in 168
patients with
hematological diseases who received MSDT in
Peking University People's
Hospital from March 2015 to November 2017. All
patients received
detection of anti-HLA
antibodies before
transplantation , and the correlation between anti-HLA
antibodies and
transplant outcomes such as hematopoietic
cells implantation,
blood product transfusion and
prognosis after
transplantation were analyzed.
Results: Among the 168
patients , 28 (16.7%) were positive for anti-HLA class Ⅰ or class Ⅱ
antibodies , and 14 (8.3%) were positive for both anti-HLA class Ⅰ and class Ⅱ
antibodies . All
patients received
neutrophil engraftment, 164
patients (97.9%) received
platelet engraftment. Univariate
analysis showed that there were no effects of anti-HLA
antibodies on
neutrophil engraftment and engraftment
time ,
platelet engraftment and engraftment
time , the volume of red
cell transfusion, the volume of
platelet transfusion , overall
survival (OS) rate,
disease free survival (DFS) rate and
transplant -related
mortality (TRM) in
patients with
hematological diseases underwent MSDT (all P > 0.05).
Multivariate analysis showed that
platelet engraftment was associated with better OS ( HR=0.065, 95% CI 0.017-0.252, P < 0.01), better DFS ( HR=0.083, 95% CI 0.024-0.289, P < 0.01) and lower TRM ( HR=0.094, 95% CI 0.014-0.626, P=0.015).
Conclusion: Anti-HLA
antibodies have no effect on
transplant outcomes of
patients with
hematological diseases who have received MSDT.